▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Maxx Chatsko

XMFBlacknGoldX

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent Articles by Maxx Chatsko

multiple lines down

Mar 9, 2020 by Maxx Chatsko

Here's Why Axsome Therapeutics Fell 10.2% in February

The development-stage pharmaceutical company gave up a little ground, but important updates are right around the corner.

302 growth stock

Mar 9, 2020 by Maxx Chatsko

5 Numbers Repligen Investors Need to Know

Drilling down in the numbers shows how the bioprocess leader became one of the best growth stocks on the market -- and how it remains well-positioned for long-term growth.

078 birds eye wastewater treatment

Mar 7, 2020 by Maxx Chatsko

Essential Utilities Takes Environmental Lead in Water, Nears Natural Gas Integration

Shares of the electric and gas utility were pounded in the broader market correction, but the long-term potential remains intact.

152 building blocks stairs

Mar 6, 2020 by Maxx Chatsko

Here's My Top Stock to Buy in March

This cellular therapy developer is valued at $2.3 billion. That could be a bargain if clinical programs impress in 2020.

464 diesel truck

Mar 5, 2020 by Maxx Chatsko

What to Watch When Renewable Energy Group Reports 2019 Results

There's really only one thing that matters to its investors with a long-term mindset: renewable diesel.

272 dominos falling stop

Mar 4, 2020 by Maxx Chatsko

Strong Growth From NeoGenomics No Match for Economic Anxieties

Growth stocks have been getting punished in the current market downturn, but investors with a long-term mindset will find plenty to like in the latest earnings report.

arrow up shelves

Mar 3, 2020 by Maxx Chatsko

Here's Why Omeros Corporation Stock Rose as Much as 46.5% Today

The company reported full-year 2019 operating results and a separate update from the pipeline.

076 arrow dude getty

Mar 2, 2020 by Maxx Chatsko

Here's Why Momenta Pharmaceuticals Stock Rose 10.8% on Monday

Investors ran back into the stock after one of the worst weeks in market history. Will it prove sustainable?

worker transmission grid

Feb 29, 2020 by Maxx Chatsko

U.S. Coal-Fired Power Plants Just Had Their Worst Year Since the 1970s

Natural gas, nuclear, wind, and solar sources had their best years of electrical output ever.

557 doctor visit

Feb 29, 2020 by Maxx Chatsko

Coronavirus: Emerging Numbers Provide Reasons for Calm

The viral outbreak is serious, but the latest numbers serve as a reminder for investors and individuals to remain objective about the health and economic risks.

563 shocked phone

Feb 29, 2020 by Maxx Chatsko

Codexis Expects Its Most Important Source of Revenue to Decline in 2020

The company expects a fourth straight year of stagnant product revenue -- and declining gross margin, to boot. Those are noteworthy red flags for investors.

534 question cards wooden box

Feb 29, 2020 by Maxx Chatsko

Will Tandem Diabetes Care Keep Its Premium Valuation in 2020?

The insulin pump manufacturer turned in a solid year of progress in 2019, but full-year 2020 guidance might be at odds with initial Wall Street expectations.

stock sliding chalkboard

Feb 28, 2020 by Maxx Chatsko

Here's Why Codexis Fell as Much as 20.0% Today

The enzyme engineering company reported disappointing full-year 2019 operating results.

stock down erased chalkboard

Feb 28, 2020 by Maxx Chatsko

Here's Why Beyond Meat Stock Tumbled as Much as 19.9% Today

The animal-free protein company reported full-year 2019 operating results and provided guidance for the year ahead.

120 fish bowl jump

Feb 28, 2020 by Maxx Chatsko

Will Puma Biotechnology Break Out of Its Rut in 2020?

The company's only drug product encountered significant obstacles to increasing its market share in 2019, but investors can see a potential path to growth.

stock down angry fist

Feb 27, 2020 by Maxx Chatsko

Here's Why NeoGenomics Fell as Much as 20.2% Today

The cancer genetics company reported full-year 2019 operating results, but that's probably not the reason for the decline.

paper airplanes rising

Feb 27, 2020 by Maxx Chatsko

Here's Why Vir Biotechnology Rose as Much as 100.1% Today

The company announced a partnership in its efforts to develop monoclonal antibodies capable of neutralizing the novel coronavirus strain.

246 nervous investor

Feb 27, 2020 by Maxx Chatsko

Lithium Demand Could Triple by 2025. Does the World Have Enough?

Peak oil has faded from the national lexicon, but some are now worrying about lithium supply. There's legitimate cause for concern, although not for the reason investors might think.

410 binoculars kid

Feb 26, 2020 by Maxx Chatsko

What to Watch When Codexis Reports 2019 Operating Results

The stock has tumbled to start 2020. Can the next business update provide any relief to shareholders?

arrow up shelves

Feb 25, 2020 by Maxx Chatsko

Here's Why Iovance Biotherapeutics Shares Soared as Much as 39.6%

Bloomberg reports that the company has been toying with the idea of a sale.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services